Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (OTCPK:AZNCF)

SumTotal Webinar Series Focuses on the Power of Pervasive and Mobile Learning

Business Wire April 8, 2014

OxySure Moves Higher after Obtaining CE Mark

Accesswire April 7, 2014

AstraZeneca Launches NEXIUM® (Esomeprazole Magnesium) Direct-to-Patient Program

Business Wire March 19, 2014

King: How the Oncology Drug Development Machine Builds Biotech Wealth

Equities.com March 17, 2014

Avanade, McAfee, SumTotal Tackle Developing Frontline Employees in Virtual Roundtable

Business Wire March 17, 2014

AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA (ticagrelor) in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session

Business Wire March 17, 2014

SumTotal Systems' CEO Hardeep Gulati to be Featured on The Bill Kutik Radio Show®

Business Wire March 11, 2014

U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

Business Wire March 3, 2014

U.S. FDA approves orphan drug MyaleptTM (metreleptin for injection)

Business Wire February 25, 2014

AstraZeneca Patient Assistance Programs Provided More Than Half a Million Patients with Free Medicine in 2013

Business Wire February 20, 2014

Bluegreen Corporation Associates Get Connected with SumTotal Social and Mobile Talent Expansion(TM) Applications

Business Wire February 13, 2014

Mid-Atlantic Lays Claim to Majority of Pharma-Biotech's $3.5 Billion Investment in Construction Starts in First-Quarter 2014, an Industrial Info News Alert

Marketwired February 11, 2014

AstraZeneca Completes Acquisition of Diabetes Alliance Assets in the U.S. from Bristol-Myers Squibb

Business Wire February 3, 2014

SumTotal elixHR(TM) Platform Takes the Gold

Business Wire January 16, 2014

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative

Business Wire January 16, 2014

Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration With AstraZeneca

Marketwired January 13, 2014

U.S. FDA Approves Farxiga(TM) (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes

Business Wire January 13, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on AZN, DD, GSK and NVS

Accesswire January 10, 2014

AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga(TM) (dapagliflozin)

Business Wire January 8, 2014

SumTotal Systems Names Hardeep Gulati Chief Executive Officer

Business Wire January 8, 2014